REGENXBIO (NASDAQ:RGNX - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($1.19) per share and revenue of $23.70 million for the quarter.
REGENXBIO Stock Performance
Shares of RGNX traded down $0.09 during trading hours on Friday, hitting $7.27. 632,908 shares of the company were exchanged, compared to its average volume of 955,200. The company has a market cap of $360.16 million, a PE ratio of -1.45 and a beta of 1.29. The firm's 50 day moving average is $7.70 and its 200-day moving average is $9.63. REGENXBIO has a 52 week low of $6.56 and a 52 week high of $28.80.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on RGNX shares. Royal Bank of Canada restated an "outperform" rating and set a $30.00 target price on shares of REGENXBIO in a research note on Tuesday, January 21st. Chardan Capital reiterated a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Wednesday, November 20th. Raymond James started coverage on REGENXBIO in a research report on Friday, February 7th. They issued an "outperform" rating and a $27.00 price objective for the company. Morgan Stanley reiterated an "overweight" rating and issued a $22.00 price objective on shares of REGENXBIO in a research report on Friday, November 15th. Finally, The Goldman Sachs Group downgraded REGENXBIO from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $38.00 to $14.00 in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, REGENXBIO currently has a consensus rating of "Moderate Buy" and a consensus price target of $33.45.
View Our Latest Research Report on REGENXBIO
About REGENXBIO
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Further Reading
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
